Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Earnings Results, Beats Estimates By $0.01 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its earnings results on Monday. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.01, FiscalAI reports. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The firm had revenue of $17.16 million for the quarter, compared to analysts’ expectations of $17.03 million.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $15.46 on Tuesday. The stock’s 50-day moving average is $13.64 and its two-hundred day moving average is $13.48. The stock has a market cap of $448.65 million, a PE ratio of -4.83 and a beta of 1.01. Enanta Pharmaceuticals has a 12 month low of $5.03 and a 12 month high of $17.15.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Finally, Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 26th. They set a “buy” rating and a $20.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $20.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC lifted its stake in shares of Enanta Pharmaceuticals by 91.6% during the fourth quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after purchasing an additional 1,782,745 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after purchasing an additional 650,000 shares in the last quarter. Krensavage Asset Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares in the last quarter. Millennium Management LLC lifted its position in shares of Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Enanta Pharmaceuticals by 0.8% during the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.